Antibiotics in Out-Patient Setting

David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle



(There are no relevant financial relationships with commercial interests to disclose

Antibiotics in Out-Patient Setting

- Respiratory Tract Infections
- Skin and Soft Tissue Infections
- Urinary Tract Infections
- Gastrointestinal Infections
- Central Nervous System Infections
- Newly Approved Out-Patient Antibiotics

Respiratory Tract Infections

Case History: Pharyngitis

- A 26-year old man is diagnosed with group A streptococcal pharyngitis. What is the likelihood that this organism is resistant to penicillin?
 - 1. 0-5%?
 - 2. 5-10?
 - 3. 20-30%
 - 4. 40-50%

Group A Streptococcal Pharyngitis

 "Penicillin-resistant group A streptococcus has never been documented."

Shulman ST, et al. Clin Infect Dis 2012;55:1279-82.

Group A Streptococcal Pharyngitis 2012 IDSA Treatment Guidelines for Adults

- Oral: Penicillin V (or Amoxicillin)
 - 250 mg qid x 10d
 - 500 mg bid x 10d
- Parenteral: Benzathine Penicillin G
 - 1.2 x 10⁶ units IM x 1
- Penicillin-Allergic Patients
 - Cephalexin
 - Cephadroxil
 - Clindamycin
 - Azithromycin
 - Clarithromycin

Source: Shulman ST, et al. Clin Infect Dis 2012;55:1279-82.

Case History: Bacterial Sinusitis

- A 22-year old woman has 11 days of nasal congestion and 3 days of purulent nasal discharge and facial pain. She is diagnosed with sinusitis.
- What treatment would you recommend?
 - 1. Trimethoprim-Sulfamethoxazole x 7 days
 - 2. Ciprofloxacin x 7 days
 - 3. Amoxicillin-clavulanic acid x 7 days
 - 4. Amoxicillin x 10 days

Acute Bacterial Rhinosinusitis Most Common Pathogens

- Streptococcus pneumoniae
- Moraxella catarrhalis
- Haemophilus influenzae
- Staphylococcus aureus
- Streptococcus pyogenes

Most Common

Less Common

Acute Bacterial Rhinosinusitis 2012 IDSA Treatment Guidelines for Adults

- Preferred Initial Therapy
 - Amoxicillin-clavulanic acid x 5-7 days
- Intranasal Corticosteroids
 Recommended—primarily if h/o allergic rhinitis
- Intranasal Saline Irrigation
 Recommended—physiologic or hypertonic
- Decongestants (Topical or Oral) or Antihistamines
 NOT recommended

Source: Chow AW, et al. Clin Infect Dis 2012;54:e72-e112.

Case History: CAP


- A healthy 48-year-old man is diagnosed with community-acquired pneumonia. He is stable and you plan to treat him as an out-patient. He has no allergies.
- Which antibiotic is recommended for this infection?
 - 1. Azithromycin
 - 2. Ciprofloxacin
 - 3. Amoxicillin-clavulanic acid
 - 4. Trimethoprim-sulfamethoxazole

Community-Acquired Pneumonia Most Common Pathogens

- Streptococcus pneumoniae
- Mycoplasma pneumoniae
- Chlamydia pneumoniae
- Haemophilus influenzae

New CAP Guidelines Projected Fall 2019

Community Acquired Pneumonia 2007 IDSA/ATS Treatment Guidelines for Adults



Source: Mandell LA et al. Clin Infect Dis. 2007;44:S27-42.

Skin and Soft Tissue

Case History

• Which one of the following is true regarding impetigo?

- 1. Penicillin is the optimal oral therapy
- 2. Group A Streptococcus alone causes >90% of cases
- 3. Patients usually have little or no systemic toxicity
- 4. If localized, Mupirocin is effective therapy



Treatment of Impetigo 2014 IDSA SSTI Guidelines

- Topical (for limited number of lesions): 7-day Rx
 - Mupirocin ointment bid x 7d
 - Retapamulin ointment x 7d
- Oral: 7-day Rx
 - Dicloxacillin
 - Cephalexin
 - Erythromycin
 - Clindamycin

Source: Stevens DL, et al. Clin Infect Dis. 2014;59:e10-52.

Skin Lesions: Ecthyma



Treatment of Ecthyma IDSA 2014 SSTI Guidelines

- Empiric Therapy
 - Cephalexin x 7d
 - Dicloxacillin x 7d
- Suspected or Confirmed MRSA
 - Doxycycline
 - Clindamycin
 - TMP-SMX

Source: Stevens DL, et al. Clin Infect Dis. 2014;59:e10-52.

MRSA SSTI





2010 IDSA Practice Guidelines Therapy for CA-MRSA Skin & Soft Tissue Infection

- Simple Abscess or Boil
 Incision and Drainage
- Complicated Abscess
 Incision and drainage + antimicrobial therapy

Source: Liu C, et al. Clin Infect Dis. 2011:52:1-38.

2010 IDSA Practice Guidelines Therapy for CA-MRSA Skin & Soft Tissue Infection

- Complicated Abscess
 - Severe or extensive disease or rapid progression of cellulitis
 - Signs and symptoms of systemic illness
 - Associated comorbidities or immunosuppression
 - Extremes of age
 - Abscess in area difficult to drain (eg, face, hand, genitalia)
 - Associated septic phlebitis
 - Lack of response to incision and drainage alone

Source: Liu C, et al. Clin Infect Dis. 2011:52:1-38.


2010 IDSA Practice Guidelines Therapy for CA-MRSA Skin & Soft Tissue Infection

- Empiric Therapy for Out-Patient Management
 - TMP-SMX: 1-2 DS tabs PO BID
 - Clindamycin: 300-450 mg PO TID
 - Doxycycline: 100 mg PO BID
 - Minocycline: 200 mg x1, then 100 mg PO BID
 - Linezolid: 600 mg PO BID
- If Also Covering for Group A Streptococcus
 - TMP-SMX + Amoxicillin: 500 mg PO TID
 - Clindamycin
 - Doxycycline/Minocycline + Amoxicillin: 500 mg PO TID
 - Linezolid

Source: Liu C, et al. Clin Infect Dis. 2011:52:1-38.

Urinary Tract Infections


Uncomplicated Cystitis in Women



Case History: UTI


- A 31-year-old woman with no major medical problems is seen in the clinic with urinary urgency, frequency, and dysuria. A urine dipstick is positive for leukocyte esterase. She has had one UTI about 3 years ago and is not pregnant? She has no allergies. Assume resistance to TMP-SMX in the community is <15%.
- Which ONE of the following is considered a preferred therapy according the 2011 IDSA Guidelines?
 - 1. TMP-SMX single dose
 - 2. Levofloxacin x single dose therapy
 - 3. Nitrofurantoin x 5d

UTI Therapy (Uncomplicated Cystitis) 2011 IDSA Guidelines



From: Gupta K, et al. Clin Infect Dis 2011:52:e103-e120.

Uncomplicated UTIs in Young Women Response Related to TMP-SMX Resistance



From: Raz R, et al. Clin Infect Dis 2002;34:1165-9.

Out-Patient Treatment of Pyelonephritis 2011 IDSA Guidelines

- Obtain Urine Cultures
- Therapy
 - Ciprofloxacin: 500 mg BID x 7 days
 - Levofloxacin 750 mg QD x 5 days
 - TMP-SMX x 14 days IF organism known susceptible
- Consider One Initial IV Dose
 - Ceftriaxone
 - Fluoroquinolone

Pyelonephritis: Ciprofloxacin vs TMP-SMX


Study Design

- Methods
 - N = 255 women
 - Acute pyelonephritis

Regimens


*Ciprofloxacin: 500 mg bid x 7d^TMP/SMX: 160/800 bid x 14d

* +/- 1 dose IV Ciprofloxacin
^ +/- 1 dose IV Ceftriaxone



From: Talan D, et al. JAMA 2000;283:1583-90.


Pyelonephritis: Ciprofloxacin vs TMP-SMX Response Related to TMP-SMX Resistance



From: Talan D et al. JAMA 2000;283:1583-90.

Gastrointestinal Infections

Clostridium *difficile*-Associated Diarrhea Pathogeneis




Asymptomatic Colonization (carrier state)

C. difficile diarrhea

Incubation range 2 days to 6 weeks


Clostridium *difficile*-Associated Diarrhea Pathogeneis

Healthy Adult




Risk Factors Antibiotics Prolonged hospital stay •Age > 65 Severe Illness •GI Surgery Nasogastric tube Antacids Stool softeners

C. difficile Colonization



Clostridium difficile Associated Diarrhea Diagnostic Tests

- Stool culture for *C*. *difficile*
 - Most sensitive, but labor intensive and slow
 - High false-positive rate (culture nontoxigenic strains)
- Antigen Detection
 Detects presence of C. difficile (not toxin)
- Toxin Genes: Molecular Tests (PCR)
 - Rapid detection of genes encoding Toxins
 - High sensitivity and specificity
- Toxin Detection: Tissue culture cytotoxic assay
 "Gold Standard" but high cost and takes >48h
- Toxin Detection: Enzyme immunoassay
 Detects toxins A and B



Case History: Hospitalized Patient with Diarrhea


- A 41-year-old man is treated for a tooth abscess with Clindamycin and 4 days after finishing the course of antibiotics he develops cramping and watery diarrhea. The patient's vital signs are normal; Serum Cr = 1.1, and WBC = 10,600. The *C. difficile* PCR toxin is positive. This is the first episode of *C. difficile* infection in this patient).
- What do you recommend for treatment in this patient based on 2017 IDSA/SHEA guidelines for adults?
 - 1. Oral Metronidazole
 - 2. Oral Vancomycin

Clostridium difficile 2017 SHEA and IDSA Clinical Practice Guidelines

Severity of Disease	Recommended Therapy: 1 st Episode for Adults
Mild-moderate WBC <15,000 AND Creatinine <1.5x baseline	Preferred Vancomycin: 125 mg 4 times daily x 10 days <i>or</i> Fidaxomicin: 200 mg twice daily x 10 days
	Alternative Metronidazole : 500 mg PO 3 times daily x 10 days

Source: McDonald LC, et al. Clin Infect Dis. 2018;66:e1-e48.

Clostridium difficile : Metronidazole vs Vancomycin Results



Source: Zar FA, et al. Clin Infect Dis. 2007;45:302-7.

Clostridium difficile 2017 SHEA and IDSA Clinical Practice Guidelines

Severity of Disease	Recommended Therapy: 1 st Episode for Adults
Severe	Preferred
WBC >15,000 <i>or</i> Creatinine ≥1.5x baseline	Vancomycin: 125 mg 4 times daily x 10 days <i>or</i> Fidaxomicin: 200 mg twice daily x 10 days

Source: McDonald LC, et al. Clin Infect Dis. 2018;66:e1-e48.

Clostridium difficile 2017 SHEA and IDSA Clinical Practice Guidelines

Severity of Disease	Recommended Therapy: 1 st Episode for Adults
Fulminant	Preferred
Hypotension	Vancomycin: 500 mg 4 times daily by mouth or
or	nasogastric tube (consider rectal instillation with ileus)
Shock	plus
or	Metronidazole: 500 mg every 8 hours IV daily
lleus	
or	
Megacolon	

Source: McDonald LC, et al. Clin Infect Dis. 2018;66:e1-e48.

Central Nervous System Infections

Case History: Meningitis

 A 57-year-old woman is seen in the ER with headache and fever and confusion. Emergent CT is normal and LP shows 8,600 WBCs (85% polys) and low glucose.

For empiric IV antibiotics, you would recommend:

- 1. Ceftriaxone
- 2. Ceftriaxone + Ampicillin
- 3. Ceftriaxone + Vancomycin
- 4. Ceftriaxone + Vancomycin + Ampicillin

Empiric Therapy for Bacterial Meningitis 2004 IDSA Treatment Guidelines for Adults


Age 18-50	Age > 50
Ceftriaxone [#]	Ceftriaxone [#]
+	+
Vancomycin [^]	Vancomycin^
+	+
Dexamethasone	Ampicillin
	+
	Dexamethasone

*Cefotaxime can be substituted for Ceftriaxone

^ Vancomycin trough should be maintained at 15-20 ug/ml

Source: Tunkel AR, et al. Clin Infect Dis. 2004:39:1267-84.

Therapy for Bacterial Meningitis in Adults




Dexamethasone in Adults with Bacterial Meningitis

Study Design

Outcome

- Methods
 - N = 301 adults
 - Acute bacterial meningitis
 - Randomized, double-blind
- Regimens
 - Dexamethasone*
 - Placebo


*10 mg 15-20 minutes before (or with) first dose of antibiotics, then q 6h x 4 days



Source: de Gans J, et al. N Engl J Med. 2002; 347:1549-56.

Newer Out-Patient Antimicrobials

Omadacycline: Mechanism of Action




ribosomal protection proteins (tet M)

Omadacycline

- FDA Approval October 2, 2018
- Antimicrobial Class
 - Aminomethycycline (within tetracycline class)
- Indications
 - Community acquired bacterial pneumonia (CABP)
 - Acute bacterial SSTI, including MRSA (ABSSTI)
- Dosing or Oral Therapy (Duration 7-14 days)
 - CABP: 200 mg IV d1, then 300 mg PO QDABSSTI: 450 mg PO days 1 and 2, then 300 mg PO QD
- Adverse Effects
 - Tooth discoloration (<8 years; last half of pregnancy)

Delafloxacin: Mechanism of Action



Equally potent against DNA gyrase and DNA topoisomerase IV enzymes

Delafloxacin

- Class: FDA Approval: June 19, 2017 for acute bacterial SSTI
- Dose:
 - Oral: 450 mg every 12 hours with or without food
 - Intravenous: 300 mg every 12 hours
- Activity:
 - Key gram-positives: MSSA, MRSA, S. pyogenes, E. faecalis
 - Key gram-negatives: E. coli, E. cloacae, P. aeruginosa
- Adverse Effects
 - Tendonitis and tendon rupture
 - Peripheral neuropathy
 - CNS: neuropsychiatric and exacerbate myasthenia gravis

Delafloxacin vs. Vancomcyin + Aztreonam for SSTI


Study Design

Clinical Success*

- Methods (N = 850)
 - Randomized, phase 3, double blind
 - Adults with SSTI/wound infection
- Regimens
 - Delafloxacin: 300 mg IV q12h x 3d, then 450 mg PO twice daily
 - Vancomycin + Aztreonam

Source: O'Riordan W. Clin Infect Dis. 2018;67:657-66. sympto


*Complete or near resolution of signs and symptoms with no further antibacterial needed.



Secnidazole

- FDA approval: September 15, 2017
- Indication: bacterial vaginosis
- Dosing: 2-g packet dose (take 1 packet)
- Formulation: packet with oral granules
 - Sprinkle on applesauce, yogurt or pudding
 - Ingest without chewing granules

Treatment of Bacterial Vaginosis with Secnidazole



Source: Hillier S, et al. Obstet Gynecol. 2017;130:379-86.

Thank you!